miR-21 attenuated inflammation targeting MyD88 in human chondrocytes stimulated with Hyaluronan oligosaccharides
Archives of Biochemistry and Biophysics · 2024
DOI: 10.1016/j.abb.2024.110112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2024. Verfasst von Michele Scuruchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy. Electronic address: mscuruchi@unime.it. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, MicroRNAs, Chondrocytes, Hyaluronic Acid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Messina.
Abstract (Originalsprache)
Inflammation is the body's response to injuries, which depends on numerous regulatory factors. Among them, miRNAs have gained much attention for their role in regulating inflammatory gene expression at multiple levels. In particular, miR-21 is up-regulated during the inflammatory response and reported to be involved in the resolution of inflammation by down-regulating pro-inflammatory mediators, including MyD88. Herein, we evaluated the regulatory effects of miR-21 on the TLR-4/MyD88 pathway in an in vitro model of 6-mer HA oligosaccharides-induced inflammation in human chondrocytes. The exposition of chondrocytes to 6-mer HA induced the activation of the TLR4/MyD88 pathway, which culminates in NF-kB activation. Changes in miR-21, TLR-4, MyD88, NLRP3 inflammasome, IL-29, Caspase1, MMP-9, iNOS, and COX-2 mRNA expression of 6-mer HA-stimulated chondrocytes were examined by qRT-PCR. Protein amounts of TLR-4, MyD88, NLRP3 inflammasome, p-ERK1/2, p-AKT, IL-29, caspase1, MMP-9, p-NK-kB p65 subunit, and IKB-a have been evaluated by ELISA kits. NO and PGE2 levels have been assayed by colorimetric and ELISA kits, respectively. HA oligosaccharides induced a significant increase in the expression of the above parameters, including NF-kB activity. The use of a miR-21 mimic attenuated MyD88 expression levels and the downstream effectors. On the contrary, treatment with a miR-21 inhibitor induced opposite effects. Interestingly, the use of a MyD88 siRNA confirmed MyD88 as the target of miR-21 action. Our results suggest that miR-21 expression could increase in an attempt to reduce the inflammatory response, targeting MyD88.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy. Electronic address: mscuruchi@unime.it.
- Department of Biomedical and Dental Sciences and Morphofunctional Images, University of Messina, 98122, Messina, Italy. Electronic address: aavenoso@unime.it.
- Department of Biomedical and Dental Sciences and Morphofunctional Images, University of Messina, 98122, Messina, Italy.
- Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.
Förderung
- University of Messina
Zitieren
APA
Scuruchi, M., Avenoso, A., Aliquò, F., Pantano, A., Campo, G. M., Campo, S., & D'Ascola, A. (2024). miR-21 attenuated inflammation targeting MyD88 in human chondrocytes stimulated with Hyaluronan oligosaccharides. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2024.110112
Vancouver
Scuruchi M, Avenoso A, Aliquò F, Pantano A, Campo GM, Campo S, et al. miR-21 attenuated inflammation targeting MyD88 in human chondrocytes stimulated with Hyaluronan oligosaccharides. Archives of Biochemistry and Biophysics. 2024. doi:10.1016/j.abb.2024.110112
BibTeX
@article{Scuruchi2024,
author = {Scuruchi, Michele and Avenoso, Angela and Aliquò, Federica and Pantano, Alice and Campo, Giuseppe M and Campo, Salvatore and D'Ascola, Angela},
title = {miR-21 attenuated inflammation targeting MyD88 in human chondrocytes stimulated with Hyaluronan oligosaccharides},
journal = {Archives of Biochemistry and Biophysics},
year = {2024},
doi = {10.1016/j.abb.2024.110112}
}
EUVIMED